Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung

Saijo, Nagahiro; Shimizu, Eiji; Shibuya, Masabumi; Irimajiri, Nobuhiro; Takizawa, T; Eguchi, Katsumi; Shinkai, Tetsu; Tominaga, Keigo; Shimabukuro, Z; Taniguchi, Takeshi; Hoshi, Akio

doi:10.1038/bjc.1982.182

Cited by 23 publications

(11 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When patients were grouped according to being free of recurrence for 4 years, the level of NK activity after two years was higher (non-significantly) than the baseline before chemotherapy; this change, if meaningful, is not readily explainable. Substantial depressions of both NK-and K-cell activity were reported be Saijo et al [14] to occur within weeks after cytotoxic chemotherapy and in their study, there was recovery shortly thereafter. We cannot state, from the present study, whether the observed decrease in NK-cell activity during chemotherapy is attributable to a relative decrease in numbers of NK cells among the population of blood mononuclear cells, or defective activity of these cells, or both.…”

Section: Discussionmentioning

confidence: 87%

Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer

Mackay

Goodyear

Riglar

et al. 1983

Cancer Immunol Immunother

View full text Add to dashboard Cite

Natural killer (NK) cell activity and antibody-dependent (K) cell activity were studied sequentially in 30 patients with early node-positive breast cancer entered into an adjuvant chemotherapy trial. The drugs used were melphalan, and melphalan with methotrexate, given for 12 months. Estimations were made 3-monthly during chemotherapy, and then at 15 and 24 months to assess recovery. Mean values for NK-cell activity during chemotherapy were significantly lower than the mean pre-chemotherapy baseline value at all time-points from 3 to 15 months, but there was recovery by 24 months. Mean values for K-cell activity during chemotherapy did not appear to differ from the mean pre-chemotherapy value, but variability in individual values was high. Over a 4-year follow-up period, a comparison of 16 patients who did not develop recurrent breast cancer with 14 who did showed that NK-cell activity was significantly lower in the latter group 12 months after the start of chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 87%

Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer

Mackay

Goodyear

Riglar

et al. 1983

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…For example, Saijo et al [18] reported improvement in NK function in patients receiving chemotherapy for lung cancer, particularly in those patients who achieved disease stabilization as a consequence of therapy. In contrast, Forbes et al [9] reported that patients with small cell carcinoma of the lung who were treated with Cytoxan, Adriamycin, and vincristine had reduced NK activity following drug treatment which persisted for extended periods of time and which was not associated with clinical treatment responses.…”

Section: Discussionmentioning

confidence: 97%

Effect of chemotherapy on NK function in the peripheral blood of cancer patients

Braun

Harris

1986

Cancer Immunol Immunother

View full text Add to dashboard Cite

The effects of cytotoxic chemotherapy on NK cell function and on glass adherent cell regulation of NK cell function was evaluated in the peripheral blood mononuclear cells of 20 previously untreated solid tumor patients. Most of the patients studied had lung cancer and received one of four combination chemotherapy treatment regimens. In addition, one patient with colon carcinoma and one patient with melanoma were studied, each of whom received treatment with a single agent. The results demonstrated that chemotherapy exerted a differential influence on NK activity which correlated with the pretreatment NK level of function in the individual patient. In patients with depressed NK levels prior to treatment, chemotherapy augmented NK function; in patients with normal levels prior to treatment, chemotherapy depressed NK function. The effects observed appeared to be associated with the capacity of chemotherapy to influence glass adherent cell regulation of NK activity. There was no apparent correlation between the effects of chemotherapy on numbers of NK effector cells, Leu11+ cells, or latex-ingesting cells. Also, there was no correlation between the effects seen and the type of drug treatment that was administered; rather, this was dependent on the pretreatment NK level of function which in turn was associated with glass adherent cell regulation of NK function.

show abstract

“…Although there are few reports in the li terature on the effect of cytotoxic agents on NK-cell activity, it was reported that cyclophosphamide and azathiopurine de press this activity in mice and that pepleomycin and carbazilquinone reduces NKcell function in man [7,15].…”

Section: Discussionmentioning

confidence: 99%

Enhancement of NK-Cell Activity in Normal and Tumor-Bearing Mice after Administration of Aclacinomycin

Mena¹,

Orbach-Arbouys²,

Mathé³

1986

Chemotherapy

View full text Add to dashboard Cite

Aclacinomycin (ACM) a new cytotoxic antibiotic employed in cancer chemotherapy, can either enhance or inhibit the NK-cell activity of the immune system, depending on the dose administered. A single intraperitoneal injection of 2–4 mg/kg of ACM augments the cytolytic activity by spleen and peritoneal exudate cells of normal mice and spleen cells depleted of nylon-adherent cells and peritoneal exudate cells of tumor-bearing mice. In contrast to the stimulatory effect of NK-cell activity by low doses of ACM, a single injection of 8 mg/kg of this agent leads to depression in the level of NK-cell activity in both normal and tumor-bearing animals. We suggest that the mechanism through which the ACM enhances NK-cell activity may be through the deletion of a suppressor cell population acting on the NK cells.

show abstract

Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung

Cited by 23 publications

References 12 publications

Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer

Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer

Effect of chemotherapy on NK function in the peripheral blood of cancer patients

Enhancement of NK-Cell Activity in Normal and Tumor-Bearing Mice after Administration of Aclacinomycin

Contact Info

Product

Resources

About